|
1
|
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
|
BJU Int
|
2008
|
2.60
|
|
2
|
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
|
Eur Urol
|
2010
|
2.47
|
|
3
|
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
|
Urology
|
2007
|
1.69
|
|
4
|
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
|
Prostate
|
2005
|
1.68
|
|
5
|
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
|
J Steroid Biochem Mol Biol
|
2005
|
1.67
|
|
6
|
Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients.
|
Am J Hum Genet
|
2010
|
1.67
|
|
7
|
Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications.
|
J Urol
|
2004
|
1.54
|
|
8
|
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
|
Endocr Relat Cancer
|
2008
|
1.30
|
|
9
|
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
|
Eur J Nucl Med Mol Imaging
|
2015
|
1.18
|
|
10
|
Long-term follow up of renal anastomosing hemangioma mimicking renal angiosarcoma.
|
Int J Urol
|
2014
|
1.09
|
|
11
|
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer.
|
J Urol
|
2006
|
1.05
|
|
12
|
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
|
BJU Int
|
2008
|
1.00
|
|
13
|
Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia.
|
Prostate
|
2003
|
0.99
|
|
14
|
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
|
J Steroid Biochem Mol Biol
|
2013
|
0.99
|
|
15
|
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.
|
Int J Public Health
|
2011
|
0.96
|
|
16
|
Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
|
J Urol
|
2005
|
0.96
|
|
17
|
Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
|
Urology
|
2005
|
0.92
|
|
18
|
Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
|
BJU Int
|
2006
|
0.91
|
|
19
|
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
|
Proc Natl Acad Sci U S A
|
2012
|
0.91
|
|
20
|
The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
|
BJU Int
|
2005
|
0.91
|
|
21
|
Quantitative measurement of the androgen receptor in prepuces of boys with and without hypospadias.
|
BJU Int
|
2013
|
0.90
|
|
22
|
Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project.
|
Eur Urol
|
2005
|
0.89
|
|
23
|
Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction.
|
BJU Int
|
2005
|
0.89
|
|
24
|
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
|
Prostate
|
2006
|
0.89
|
|
25
|
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?
|
BJU Int
|
2008
|
0.87
|
|
26
|
Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
|
J Urol
|
2007
|
0.84
|
|
27
|
Multiparametric magnetic resonance imaging/transrectal ultrasound fusion targeted biopsy of the prostate: preliminary results of a prospective single-centre study.
|
Urol Int
|
2015
|
0.84
|
|
28
|
Comparison of real-time elastography and multiparametric MRI for prostate cancer detection: a whole-mount step-section analysis.
|
AJR Am J Roentgenol
|
2014
|
0.84
|
|
29
|
The influence of prostate volume on prostate cancer detection using a combined approach of contrast-enhanced ultrasonography-targeted and systematic grey-scale biopsy.
|
BJU Int
|
2007
|
0.83
|
|
30
|
Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
|
Mol Carcinog
|
2003
|
0.81
|
|
31
|
Endoscopic treatment of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer in children: results of postoperative follow-up with real-time 3D sonography.
|
Urol Int
|
2011
|
0.81
|
|
32
|
Adverse pathological findings in needle biopsy gleason score 6 prostate cancers with low and intermediate preoperative PSA levels following radical prostatectomy.
|
Anticancer Res
|
2012
|
0.81
|
|
33
|
Potentials and limitations of real-time elastography for prostate cancer detection: a whole-mount step section analysis.
|
ScientificWorldJournal
|
2012
|
0.80
|
|
34
|
Phytoestrogens derived from Belamcanda chinensis have an antiproliferative effect on prostate cancer cells in vitro.
|
J Urol
|
2004
|
0.79
|
|
35
|
Influence of blood sampling on protein profiling and pattern analysis using matrix-assisted laser desorption/ionisation mass spectrometry.
|
BJU Int
|
2007
|
0.79
|
|
36
|
Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy.
|
Anticancer Res
|
2014
|
0.77
|
|
37
|
Models to predict positive prostate biopsies using the Tyrol screening study.
|
Urology
|
2011
|
0.77
|
|
38
|
Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
|
Urology
|
2006
|
0.77
|
|
39
|
Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.
|
Int J Mol Sci
|
2013
|
0.75
|
|
40
|
Hydronephrosis Predicts Successful Catheter Removal after Painful Urinary Retention - Preliminary Results of a Prospective Single Center Study.
|
Urol Int
|
2015
|
0.75
|
|
41
|
Clinically insignificant improvement of prostate cancer prediction by addition of sex steroid hormones and SHBG serum levels to serum PSA, fPSA%, and age in a screening setting.
|
Horm Mol Biol Clin Investig
|
2012
|
0.75
|
|
42
|
The need for repeated urological evaluation in low-risk patients with microscopic hematuria after negative diagnostic work-up.
|
Anticancer Res
|
2013
|
0.75
|
|
43
|
Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
|
BJU Int
|
2008
|
0.75
|